To uncover the link between BCL6 expression and clinical outcomes in KRAS-mutant lung cancer, we further examined BCL6 expression in human LUAD tissue, including KRAS-mutant subgroup (n = 62) and KRAS WT subgroup (n = 67). Here, KRAS is linked to lung carcinoma.